Leukotriene B4 produces hyperalgesia that is dependent on polymorphonuclear leukocytes.
Leukotriene B4, at the same intracutaneous doses as bradykinin, reduced the nociceptive threshold in the rat paw. The mechanism of leukotriene B4-induced hyperalgesia was distinguished from that of the hyperalgesia elicited by prostaglandin E2 and bradykinin by its dependence on polymorphonuclear leukocytes and independence of the cyclooxygenation of arachidonic acid.
D000700:Analgesics / Q000494:pharmacology*; D000818:Animals; D001920:Bradykinin / Q000494:pharmacology; D015232:Dinoprostone; D007213:Indomethacin / Q000494:pharmacology; D007975:Leukotriene B4 / Q000031:analogs & derivatives / Q000494:pharmacology*; D008297:Male; D009504:Neutrophils / Q000187:drug effects* / Q000502:physiology; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism; D011458:Prostaglandins E / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D013189:SRS-A / Q000494:pharmacology
D000700:Analgesics; D011458:Prostaglandins E; D013189:SRS-A; D007975:Leukotriene B4; C030722:8,15-leukotriene B4; D011451:Prostaglandin-Endoperoxide Synthases; D015232:Dinoprostone; D001920:Bradykinin; D007213:Indomethacin